The Multi-Agency SBIR Strategy: How Serial Winners Build a Portfolio Across DOD, NIH, and NSF

Between 2009 and 2019, ninety-five companies captured more than 21 percent of all SBIR awards issued by the federal government. That finding, published by the State Science & Technology Institute, triggered a five-month authorization lapse, a bipartisan congressional crackdown, and a reauthorization bill that passed the House 345 to 41 in March 2026. The debate over SBIR mills consumed Washington for the better part of two years.

But buried in the outrage over Physical Sciences Inc.'s 1,728 awards ($650 million since 1983) and Triton Systems' 906 awards ($365 million) was a quieter fact: not every multi-agency SBIR company is a mill. Some of the most consequential defense and health technologies of the past two decades emerged from companies that deliberately built award portfolios across the Department of Defense, National Institutes of Health, National Science Foundation, and beyond. The reauthorization did not outlaw that strategy. It clarified the line between a portfolio and a racket.

For companies with genuine technology platforms, the multi-agency approach remains the single most underutilized strategy in the $4 billion SBIR ecosystem. Here is how the best operators execute it.

The $4 Billion Funding Map

Eleven federal agencies participate in SBIR, each setting aside between 1.5 and 3.2 percent of its extramural research budget. The funding distribution is heavily skewed. DOD accounts for roughly 48 percent of all SBIR dollars -- approximately $1.8 billion in fiscal year 2025, spread across the Army, Navy, Air Force, Space Force, DARPA, MDA, DTRA, SOCOM, the Defense Health Agency, and the Chemical and Biological Defense Program. The Department of Health and Human Services follows at 31 percent, with NIH alone distributing approximately $1.2 billion through its 27 institutes and centers. DOE, NSF, and NASA together account for another 19 percent.

This concentration creates a map with clear strategic implications. A company whose technology serves only one agency's mission competes for one slice of the $4 billion pool. A company whose core platform credibly addresses two or three agency missions can tap noncompeting funding streams without ever submitting duplicate work.

CFD Research Corporation, headquartered in Huntsville, Alabama, has operated this way for decades. Founded on computational fluid dynamics modeling, CFD Research has won SBIR awards from the Air Force, Army, DARPA, NASA, DOE, NSF, NIH, and DHS. Its simulation software, originally funded under defense SBIR contracts, was adapted for biomedical modeling (NIH), energy systems analysis (DOE), and materials science applications (NSF). The company has received the SBA Tibbetts Award twice and converted Phase II work into a $10 million Phase III IDIQ contract with the Air Force Research Laboratory. No one in Congress has proposed shutting CFD Research down.

The distinction matters because it governs how you plan. A company that treats SBIR as eleven separate grant programs will write eleven disconnected proposals. A company that maps its technology platform against the mission needs of three or four agencies and builds a sequenced portfolio is playing a fundamentally different game.

Three Agencies, Three Cultures, Three Evaluation Frameworks

The fastest way to fail at a multi-agency strategy is to assume that SBIR is one program with eleven portals. Each agency evaluates proposals differently, uses a different review structure, and weights different factors. Winning across agencies requires understanding what each one actually cares about.

DOD operates topic-driven solicitations. Companies respond to specific acquisition needs published by individual service branches and defense agencies through the Defense SBIR/STTR Innovation Portal (DSIP). Reviewers are typically government scientists and program managers assessing whether the proposed technology solves a defined military problem. Evaluation criteria emphasize technical merit and innovation relative to the state of the art, qualifications of key investigators, and potential for transition into acquisition programs or commercial markets. DOD reviews are conducted internally -- there is no external peer review panel. Phase I awards reach $200,000, and Phase II awards average approximately $1.16 million.

The cultural reality at DOD is that program managers are looking for technologies they can buy. Proposals succeed when they demonstrate not just scientific novelty but a clear pathway to a defense system or platform integration. Letters of support from primes, transition agreements, or evidence of prior military end-user engagement carry significant weight.

NIH uses a dual-review system modeled on the broader NIH grants process. External peer review panels (study sections) evaluate scientific and technical merit, assigning priority scores. An internal advisory council then reviews the scored applications for programmatic relevance. NIH reviewers assess five criteria: significance, investigator qualifications, innovation, approach, and environment. Commercialization potential is evaluated as a sixth factor under the SBIR-specific review criteria.

NIH's culture is fundamentally scientific. Proposals must demonstrate rigorous experimental design, preliminary data (for competitive submissions), and alignment with disease-burden priorities set by individual institutes. Phase I awards reach approximately $307,000, and Phase II awards can exceed $2 million -- the highest in the SBIR ecosystem. The success rate for Phase I hovers between 15 and 18 percent, making NIH the most competitive agency by that measure.

NSF applies two criteria to every proposal: Intellectual Merit and Broader Impacts. NSF uses a unique two-step process for SBIR: companies first submit a three-page Project Pitch describing their innovation and its commercial potential. Only companies that receive an invitation may submit full proposals. This screening mechanism filters out roughly 60 to 75 percent of pitches before any full proposal is written. Reviewers include external panelists and mail reviewers who evaluate whether the technology advances fundamental knowledge, the team is qualified, and the work will benefit society beyond the proposing company.

NSF's culture values deep technical innovation and, distinctly among SBIR agencies, weighs broader societal impacts as a co-equal criterion. A proposal that describes a technically brilliant sensor but cannot articulate who benefits beyond the company will score poorly. Phase I awards reach $305,000, and Phase II awards reach $1.25 million.

A single proposal written to satisfy DOD's acquisition-oriented reviewers will confuse NIH study sections expecting experimental rigor. A proposal crafted for NIH's scientific culture will bore NSF reviewers looking for societal transformation. The technology can overlap. The framing cannot.

The Staggered Pipeline: Turning Calendar Differences into Competitive Advantage

The agencies operate on different solicitation schedules, and smart multi-agency companies exploit the gaps.

DOD releases SBIR solicitations in cycles, typically three per fiscal year, with each cycle containing 200 to 400 topics. Open periods run 30 to 60 days. Some components also accept proposals on a rolling basis through Open Topic solicitations. NIH has historically used three standard receipt dates per year -- January 5, April 5, and September 5 -- for omnibus SBIR applications. NSF accepts Project Pitches on a rolling basis and responds within about 30 days; full proposals are due on agency-specified dates after invitation.

This asynchrony is not an inconvenience. It is the operational foundation of a multi-agency portfolio. A company running a three-person proposal team can allocate Q1 to a DOD topic response, shift to NIH in Q2 targeting the September receipt date with adequate time for preliminary data analysis, use Q3 to pitch NSF on a complementary technology angle, and prepare a DOE or NASA submission for the fall cycle.

The compounding effect of a staggered pipeline is substantial. Preliminary data generated under a DOD Phase I strengthens a subsequent NIH proposal's approach section. An NIH Phase I validation study produces exactly the kind of evidence NSF reviewers want to see. A DOE Phase II prototype reduces technical risk for a follow-on DOD Phase II proposal. Each award feeds the next application, and the staggered schedule prevents the resource bottleneck that kills most multi-agency attempts: writing four proposals simultaneously with the same team.

Creare LLC, an engineering firm based in Hanover, New Hampshire, has executed this model across decades. The company has won SBIR awards from NASA, DOD (including Army, Navy, and Air Force components), NIH, DOE, and NSF. Its core expertise in thermal and fluid systems engineering has been applied to spacecraft life support systems (NASA), military cooling technologies (DOD), medical device thermal management (NIH), and clean energy heat exchangers (DOE). Creare has transitioned multiple Phase II projects into Phase III contracts and commercial products, including cryogenic cooling systems now used in satellite and defense applications.

Drawing the Line: Portfolio Strategy vs. SBIR Mill

The reauthorization bill that passed the House on March 17, 2026 -- the Small Business Innovation and Economic Security Act -- does not prohibit multi-agency strategies. It targets companies that treat SBIR as a permanent revenue stream without commercializing their outputs.

The evidence Congress relied on was damning. GAO analysis found that the highest-volume SBIR awardees produced patents at a rate of 3.4 percent, compared to 4 to 5 percent for companies with fewer awards. DefenseScoop reported that top serial awardees generated just $0.89 in commercial revenue per Phase II dollar received. They were winning grants, publishing reports, and recycling proposal language -- but not building products, attracting customers, or transitioning technology into government acquisition programs.

The bill addresses this with three mechanisms. First, each agency must establish caps on the number of proposals any single company can submit per solicitation cycle. Agencies retain discretion over limits -- by fiscal year, by solicitation, or by topic -- but the SBA will enforce a government-wide floor. Second, waivers to exceed caps require written justification, senior-level approval, and notification to congressional committees. Waivers are capped at 5 percent of topics annually per agency. Third, Phase II evaluations now include mandatory commercialization benchmarking, with agencies directed to weigh prior Phase III conversion rates and commercial revenue when scoring proposals from repeat awardees.

The practical effect is that volume strategies are dead. Companies that previously submitted 40 or 50 Phase I proposals per cycle will hit hard limits. But a company that submits two well-targeted DOD proposals, one NIH application, and one NSF pitch per year -- each addressing a distinct technical problem for a different agency mission -- is operating well within any plausible cap.

The distinction boils down to one question: does each award advance a distinct technical objective toward a real product or contract, or does it fund overlapping work with no end market?

The Strategic Breakthrough Awards: Where Multi-Agency Portfolios Pay Off

The most consequential provision in the 2026 reauthorization creates Strategic Breakthrough Awards -- a post-Phase II funding mechanism offering up to $30 million over 48 months. Only agencies with $100 million or more in annual SBIR obligations may issue them, which limits eligibility to DOD, HHS (through NIH), DOE, NASA, and NSF. Funding is capped at 0.50 percent of each qualifying agency's extramural R&D budget.

The catch is a 100 percent matching requirement. A company seeking a $10 million Strategic Breakthrough Award must demonstrate $10 million in matching capital from private investment, non-SBIR government contracts, or commercial revenue. A company seeking the full $30 million needs $30 million in match.

This is where a multi-agency portfolio creates decisive advantage. A company that has won Phase I and Phase II awards from DOD and NIH has demonstrated product-market fit across two federal missions. If that company also has a DOD Phase III contract or NIH follow-on award, it has both the track record and the matching funds to compete for Strategic Breakthrough Awards. A company with 200 Phase I awards and no Phase III contracts has neither.

The math is straightforward. A Phase II award from DOD ($1.16 million average) plus a Phase II from NIH (up to $2 million) plus a DOD Phase III contract ($2-5 million typical) generates the kind of revenue and validation that unlocks a Strategic Breakthrough application. The portfolio strategy is not just about accumulating awards -- it is about building the commercial traction that the new post-Phase II funding requires.

Compliance at Scale: The Operational Challenge Nobody Talks About

Running simultaneous awards across multiple agencies is where ambition collides with accounting. Each agency imposes its own reporting cadence, financial management standards, and intellectual property provisions. Companies that scale a multi-agency portfolio without scaling their back office do not survive audits.

Financial management is the first point of failure. DOD awards frequently require DCAA-compliant accounting systems with project-level cost accumulation, labor-hour timekeeping by contract, indirect cost allocation using documented and consistently applied rates, and audit-ready financial reporting. NIH requires progress reports tracking milestones and commercialization plan updates. NSF mandates annual and final project reports through Research.gov. A company running awards across all three agencies must satisfy three distinct reporting regimes with compatible but not identical data.

The solution is installing project-level cost accounting before winning the second award. Retrofitting accounting after a DCAA audit finding is exponentially more expensive -- and an adverse finding on one agency's award can cascade into reviews of every federal contract the company holds.

Intellectual property is the second failure point. DOD contracts may require the government to receive unlimited rights to certain deliverables, depending on funding source and data rights clauses negotiated at award. NIH grants generally preserve the small business's patent rights under the Bayh-Dole Act. NSF follows Bayh-Dole as well but requires disclosure and election of title within specific timeframes. When the same underlying technology platform generates deliverables for multiple agencies, unclear IP boundaries create conflicts that can jeopardize every award in the portfolio.

Disclosure obligations are the third. Every agency requires reporting of current and pending support. A company holding three active SBIR awards and applying for a fourth must disclose all three, and reviewers will scrutinize the relationship between the proposed work and existing funded efforts. Inadequate disclosure -- or the appearance of overlapping scope -- triggers investigations that can result in award termination and debarment.

Three practices mitigate these risks. First, hire or contract a compliance specialist before the second award, not after the first audit. Second, maintain separate project files, budgets, and deliverable repositories for each award, even when the underlying technology overlaps. Third, document distinct scopes of work for every proposal with enough specificity that an auditor can distinguish what each award funded.

The Post-Reauthorization Window

The five-month SBIR authorization lapse created a backlog of unfunded research priorities across every participating agency. DOD and NIH are expected to publish the first post-reauthorization solicitations in spring 2026, with NSF, DOE, and NASA following through early summer. Companies that used the shutdown period to map their technology platforms against multiple agency mission needs have a structural advantage over those now scrambling to restart.

The new proposal caps will thin the field of volume submitters. For companies with genuine cross-agency technology, reduced competition from serial filers means better odds on each individual proposal. Phase I success rates have historically averaged around 15 to 20 percent across most agencies, with some DOD components reaching 22 to 25 percent for well-matched topics. Phase II conversion rates run substantially higher -- around 59 percent government-wide. A company that wins Phase I awards from two agencies and converts even one to Phase II is building a portfolio worth $1.5 to $2.5 million in non-dilutive funding within 18 to 24 months.

The companies that will dominate the next cycle of SBIR are not the ones that submit the most proposals. They are the ones that identify two or three agency missions their technology can credibly serve, build staggered submission pipelines, invest in compliance infrastructure, and convert Phase I and Phase II awards into the commercial traction that unlocks Strategic Breakthrough funding. The multi-agency strategy did not die with the reauthorization. It grew up.

Granted tracks SBIR solicitations across all eleven participating agencies and matches them to your technology profile, so you can build a cross-agency pipeline without manually scanning thousands of topics.